GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent lawsuit with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster painkiller Celebrex in December.

  • April 17- Teva Pharmaceutical Industries Ltd said it settled a patent litigation with Pfizer Inc, allowing the Israeli drugmaker to launch a generic version of Pfizer's blockbuster pain medication, Celebrex, in December. Celebrex's basic chemical patent expires on May 30.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • MUMBAI, April 9- India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States after completing a $3.2 billion takeover of its loss-making rival, sources with direct knowledge of the matter said.

  • Chief Justice John Roberts on Tuesday asked generic drug manufacturers to respond to a request from Teva Pharmaceutical Industries Ltd seeking to prevent a lower court ruling from taking effect while the high court considers an appeal in a patent fight over Teva's top-selling multiple sclerosis drug, Copaxone.

  • Teva launches generic version of fish oil drug Tuesday, 8 Apr 2014 | 10:47 AM ET

    NEW YORK— Teva Pharmaceutical Industries said Tuesday it is now selling a generic version of the heart medication Lovaza, which is used to treat high triglyceride levels.

  • WASHINGTON, April 7- Teva Pharmaceutical Industries Ltd asked the U.S. Supreme Court on Monday to stop a lower court ruling from going into effect while the justices consider an appeal in a patent fight over Teva's top-selling multiple sclerosis drug Copaxone.

  • March 31- Eli Lilly was successful in a crucial legal battle on Monday when a U.S. The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the' 209 Patent are invalid.

  • WASHINGTON, March 31- The U.S. Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone, a move that could deter generic manufacturers from introducing cheaper versions onto the market as soon as May.

  • U.S. justices agree to hear Teva's Copaxone appeal Monday, 31 Mar 2014 | 9:36 AM ET

    By agreeing to hear the case, the high court cast into doubt a July 2013 ruling by the U.S. Court of Appeals for the Federal Circuit in favor of two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta Pharmaceuticals Inc and another involving Mylan Inc and Natco Pharma Ltd. The appeals court upheld some of nine patents involved in the drug, or portions thereof, but declared several invalid, meaning patent protections were set to expire in May 2014 instead of September 2015.

  • In the short term, that is expected to benefit larger global competitors, such as Teva Pharmaceutical Industries Ltd, Actavis Plc and Mylan Inc, which will be called upon to supply drugs no longer available from some of their rivals in India, they said.

  • WASHINGTON, March 24- The U.S. Supreme Court on Monday for the second time did not announce whether it would hear an appeal by Teva Pharmaceutical Industries Ltd in a patent fight with generic competitors over a top-selling multiple sclerosis drug.

  • U.S. top court takes no action in Teva MS drug case Monday, 24 Mar 2014 | 10:42 AM ET

    WASHINGTON, March 24- The U.S. Supreme Court on Monday for the second time did not announce whether it would hear an appeal by Teva Pharmaceutical Industries Ltd in a patent fight with generic competitors over a top-selling multiple sclerosis drug.

  • Your first trade for Monday Friday, 14 Mar 2014 | 1:15 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Midday movers: Castlight Health, Coach, Ann & More Friday, 14 Mar 2014 | 12:11 PM ET

    Some of Friday's midday movers:

  • March 13- Generic injectable drugs maker Sagent Pharmaceuticals Inc is looking to shore up its portfolio with deals worth up to $500 million, as rampant manufacturing issues and quality concerns push consolidation in the industry.

  • Court voids key Celebrex patent; Pfizer to appeal Wednesday, 12 Mar 2014 | 2:15 PM ET
    Pfizer

    Pfizer said a court had invalidated a key patent behind its blockbuster Celebrex drug, and plans to appeal the judgement.

  • March 11- Teva Pharmaceutical Industries Ltd agreed to pay $27.6 million to settle charges that it paid kickbacks to a Chicago psychiatrist to induce him to prescribe an anti-schizophrenia drug to patients, resulting in more than 100,000 false Medicaid and Medicare claims.

  • Harness outsized gains with Cramer stock strategy Thursday, 27 Feb 2014 | 6:00 PM ET

    Cramer honestly believes that regular investors can outperform the broad market every day, including today, simply by following this strategy.

  • Your first trade for Friday Thursday, 27 Feb 2014 | 1:38 PM ET

    The "Fast Money" traders share their final trades of the day.

Most Popular Video

Thursday, 17 Apr 2014 | 9:52 AM ET

CNBC's Allison Linn reports on new research that shows how employees who do something creative after work—like knitting, drawing or even playing a creative video game—are more likely to be helpful and creative problem solvers on the job.

Thursday, 17 Apr 2014 | 9:04 AM ET

CNBC's Jim Cramer breaks down General Electric's quarterly results and reveals the 2 big growth areas he sees in the economy.

Thursday, 17 Apr 2014 | 8:52 AM ET

Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Cramer reflects on his years at CNBC.